Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated:  12/31/1969
Research site
3356
mi
from 91732
San Juan,
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated: 12/31/1969
Research site
3356
mi
from 91732
San Juan,
Click here to add this to my saved trials
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection
A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1573
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Miami VA Healthcare System, Miami, FL
2319
mi
from 91732
Miami, FL
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Miami VA Healthcare System, Miami, FL
2319
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
2301
mi
from 91732
Baltimore, MD
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2578
mi
from 91732
Boston, MA
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
1926
mi
from 91732
Ann Arbor, MI
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
1926
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Minneapolis VA Health Care System, Minneapolis, MN
1509
mi
from 91732
Minneapolis, MN
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Minneapolis VA Health Care System, Minneapolis, MN
1509
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
1294
mi
from 91732
Omaha, NE
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
1294
mi
from 91732
Omaha, NE
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Portland Health Care System, Portland, OR
827
mi
from 91732
Portland, OR
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Portland Health Care System, Portland, OR
827
mi
from 91732
Portland, OR
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
South Texas Health Care System, San Antonio, TX
1182
mi
from 91732
San Antonio, TX
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
South Texas Health Care System, San Antonio, TX
1182
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
VA Salt Lake City Health Care System, Salt Lake City, UT
570
mi
from 91732
Salt Lake City, UT
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
VA Salt Lake City Health Care System, Salt Lake City, UT
570
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated:  12/31/1969
Iowa City VA Health Care System, Iowa City, IA
1529
mi
from 91732
Iowa City, IA
Building an Optimal Hand Hygiene Bundle
Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach
Status: Enrolling
Updated: 12/31/1969
Iowa City VA Health Care System, Iowa City, IA
1529
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
MENVEO® Pregnancy Registry: an Observational Study on the Safety of MENVEO Exposure in Pregnant Women and Their Offspring
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
2282
mi
from 91732
Wilmington, NC
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
MENVEO® Pregnancy Registry: an Observational Study on the Safety of MENVEO Exposure in Pregnant Women and Their Offspring
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
2282
mi
from 91732
Wilmington, NC
Click here to add this to my saved trials
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis
A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1188
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)
Status: Enrolling
Updated:  12/31/1969
University of Maryland, R Adams Cowley Shock Trauma Center
2301
mi
from 91732
Baltimore, MD
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)
Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)
Status: Enrolling
Updated: 12/31/1969
University of Maryland, R Adams Cowley Shock Trauma Center
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Medical Center, Fairview
1511
mi
from 91732
Minneapolis, MN
MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Medical Center, Fairview
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC (Research Site)
358
mi
from 91732
Chandler, AZ
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC (Research Site)
358
mi
from 91732
Chandler, AZ
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Center for Clinical Trials, LLC.
14
mi
from 91732
Paramount, CA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Center for Clinical Trials, LLC.
14
mi
from 91732
Paramount, CA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
California Research Foundation
103
mi
from 91732
San Diego, CA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
California Research Foundation
103
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Bayview Research Group
22
mi
from 91732
Valley Village, CA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Bayview Research Group
22
mi
from 91732
Valley Village, CA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
USF Health South Tampa Center for Advanced Healthcare
2136
mi
from 91732
Tampa, FL
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
USF Health South Tampa Center for Advanced Healthcare
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
USF Health
2136
mi
from 91732
Tampa, FL
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
USF Health
2136
mi
from 91732
Tampa, FL
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
North Georgia Research Clinical Center
1983
mi
from 91732
Dalton, GA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
North Georgia Research Clinical Center
1983
mi
from 91732
Dalton, GA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Pediatrics & Adolescent Medicine, Pa
1911
mi
from 91732
Marietta, GA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Pediatrics & Adolescent Medicine, Pa
1911
mi
from 91732
Marietta, GA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
664
mi
from 91732
Meridian, ID
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
664
mi
from 91732
Meridian, ID
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
1201
mi
from 91732
Augusta, KA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
1201
mi
from 91732
Augusta, KA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Kentucky Pediatric/ Adult Research
1829
mi
from 91732
Bardstown, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Kentucky Pediatric/ Adult Research
1829
mi
from 91732
Bardstown, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Brownsboro Park Pediatrics
1818
mi
from 91732
Louisville, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Brownsboro Park Pediatrics
1818
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Bluegrass Clinical Research
1823
mi
from 91732
Louisville, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Bluegrass Clinical Research
1823
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Southwestern Medical Clinic, Lakeland HealthCare Affiliate
1787
mi
from 91732
Stevensville, MI
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Southwestern Medical Clinic, Lakeland HealthCare Affiliate
1787
mi
from 91732
Stevensville, MI
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
1339
mi
from 91732
Kansas City, MO
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
1339
mi
from 91732
Kansas City, MO
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
1276
mi
from 91732
Fremont, NE
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC
1276
mi
from 91732
Fremont, NE
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Midwest Children'S Health Research Institute
1257
mi
from 91732
Lincoln, NE
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Midwest Children'S Health Research Institute
1257
mi
from 91732
Lincoln, NE
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Nevada
218
mi
from 91732
Henderson, NV
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Nevada
218
mi
from 91732
Henderson, NV
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Ohio Pediatric Research Association, Inc
1897
mi
from 91732
Dayton, OH
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Ohio Pediatric Research Association, Inc
1897
mi
from 91732
Dayton, OH
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Ohio Pediatrics, Inc
1896
mi
from 91732
Dayton, OH
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Ohio Pediatrics, Inc
1896
mi
from 91732
Dayton, OH
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
West Houston Clinical Research Service (WHCRS)
1358
mi
from 91732
Houston, TX
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
West Houston Clinical Research Service (WHCRS)
1358
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
J. Lewis Research Inc.-Foothill Family Clinic
572
mi
from 91732
Salt Lake City, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
J. Lewis Research Inc.-Foothill Family Clinic
572
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
J. Lewis Research, Inc. / Foothill Family Clinic South
565
mi
from 91732
Salt Lake City, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
J. Lewis Research, Inc. / Foothill Family Clinic South
565
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
J. Lewis Research, Inc. / Jordan River Family Medicine
558
mi
from 91732
South Jordan, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
J. Lewis Research, Inc. / Jordan River Family Medicine
558
mi
from 91732
South Jordan, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research, Inc.
559
mi
from 91732
West Jordan, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research, Inc.
559
mi
from 91732
West Jordan, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
The Vancouver Clinic, Inc, PS
828
mi
from 91732
Vancouver, WA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
The Vancouver Clinic, Inc, PS
828
mi
from 91732
Vancouver, WA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Monroe Clinic
1637
mi
from 91732
Monroe, WI
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Monroe Clinic
1637
mi
from 91732
Monroe, WI
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Pediatrics and Adolescent Medicine
1907
mi
from 91732
Woodstock, GA
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Pediatrics and Adolescent Medicine
1907
mi
from 91732
Woodstock, GA
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Ordinace praktickeho lekare pro deti a dorost
1731
mi
from 91732
Holice,
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Ordinace praktickeho lekare pro deti a dorost
1731
mi
from 91732
Holice,
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Research and Education Association for Clinical Health, Inc.
1637
mi
from 91732
Monroe, WI
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Research and Education Association for Clinical Health, Inc.
1637
mi
from 91732
Monroe, WI
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
U of L Pediatrics: Downtown
1813
mi
from 91732
Louisville, KY
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
U of L Pediatrics: Downtown
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Dr. Shelly David Senders, MD Inc. dba Senders Pediatrics
2032
mi
from 91732
Cleveland, OH
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Dr. Shelly David Senders, MD Inc. dba Senders Pediatrics
2032
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
BB Holdings, LLC., dba Jean Brown Research
570
mi
from 91732
Salt Lake City, UT
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
BB Holdings, LLC., dba Jean Brown Research
570
mi
from 91732
Salt Lake City, UT
Click here to add this to my saved trials
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated:  12/31/1969
Creighton University Pediatric Infectious Diseases
1295
mi
from 91732
Omaha, NE
Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose
A Phase 3 Study To Assess The Persistence Of Hsba Response Up To 48 Months After Completion Of A Primary Series Of Bivalent Rlp2086, And The Safety, Tolerability, And Immunogenicity Of A Booster Dose Of Bivalent Rlp2086
Status: Enrolling
Updated: 12/31/1969
Creighton University Pediatric Infectious Diseases
1295
mi
from 91732
Omaha, NE
Click here to add this to my saved trials